ACT-CTU Clinical Trial Rounds - September 28, 2026

ACT-CTU Clinical Trial Rounds - September 28, 2026

🎙 Centre for Outcomes Research and Evaluation - Research Institute McGill University Health Centre 👥 390 📅 September 29, 2026 ⏱ 62 min 👁 27 📄 science communication 🧭 2026-10-08
Available in: English (current) Français

Keywords

Sequential Multiple Assignment Randomized Trialadaptive interventionprecision medicinescoping reviewbehavioral intervention

Summary

This webinar, part of the ACT-CTU Clinical Trial Rounds, features two experts: Dr. Erica Moodie, a biostatistician, and Dr. Sylvie Lambert, a nursing researcher. Dr. Moodie begins with an overview of Sequential Multiple Assignment Randomized Trials (SMARTs), explaining their purpose in building adaptive interventions for chronic conditions where treatment response is heterogeneous. She uses a toy example of major depressive disorder to illustrate how two separate single-stage trials can fail to identify the optimal treatment sequence, whereas a SMART can. She then clarifies that SMARTs are not adaptive trials (which modify trial design elements) nor crossover trials (which evaluate standalone treatments with washout periods). Dr. Lambert follows with a scoping review of SMARTs in behavioral interventions for chronic physical and mental illness, covering 16 studies (15 unique) published mostly since 2018. She describes three common SMART designs and provides examples, including their own pilot SMART for cancer patients and caregivers using self-management interventions. The session includes interactive Q&A clarifying design distinctions and applications to combination treatments. Overall, the presentation is methodologically sound and provides a clear introduction to SMART designs for a clinical trials audience.

185 words

Critical Evaluation

Value of the Information & Strength of the Argument

The presentation offers high informational value by clearly articulating the rationale for SMART designs: when patient responses are heterogeneous, standard two-arm trials may not capture delayed effects or synergies between treatment stages, leading to suboptimal treatment sequences. The toy example effectively demonstrates how two separate trials can suggest a suboptimal sequence (e.g., starting with sertraline then CBT) while a SMART could reveal that starting with CBT then sertraline yields a higher overall response rate. The argument is logically structured, moving from the problem (heterogeneity, need for adaptation) to the solution (SMARTs) and then to practical applications. The Q&A session adds depth by addressing nuanced questions about combination treatments and the distinction from adaptive trials. The scoping review provides empirical grounding, showing that SMARTs are increasingly used in behavioral interventions, though the review is limited to 16 studies, indicating a still-emerging field. The argumentation is balanced, acknowledging that SMARTs are not always necessary and that they are fixed-design trials. The value is further enhanced by the practical examples from the presenters’ own work, making the abstract statistical concepts concrete.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high, with both presenters being established experts: Dr. Moodie is a Canada Research Chair and fellow of the American Statistical Association, and Dr. Lambert holds a CIHR New Investigator Award. The content is methodologically precise, with clear definitions and distinctions. However, the presentation does not include a formal reference list or citations for the scoping review or the toy example, which limits the ability to verify specific claims. The scoping review is mentioned but not cited with a DOI or journal, and no external sources are provided in the description. The title accurately reflects the content, indicating a clinical trial rounds session on SMART designs. The session is part of an academic webinar series, which adds credibility. The lack of explicit sources is a minor weakness, but the expertise of the presenters and the institutional context mitigate this. The Q&A demonstrates engagement and clarification of concepts, further supporting the rigor.

347 words

Title / Content Match

The title accurately reflects the content: it is a clinical trial rounds session focused on Sequential Multiple Assignment Randomized Trial (SMART) designs, delivered on the stated date. The title is generic but not misleading.

Quality & Reliability

8/10

Presented by two recognized experts (a Canada Research Chair in statistical methods for precision medicine and an associate professor in nursing) within an academic clinical trials unit webinar. The content is methodologically rigorous, clearly distinguishing SMARTs from adaptive and crossover trials, and grounded in a scoping review. No conflicts of interest are apparent. The main limitation is the absence of a full reference list in the description and the reliance on a single scoping review for the behavioral intervention section.

Key Moments

Contribution & Novelties

The presentation provides a clear and accessible introduction to SMART designs, distinguishing them from adaptive and crossover trials, and offers a scoping review of their application in behavioral interventions. The novelty lies in the synthesis of statistical methodology with practical behavioral intervention examples, particularly the pilot SMART for cancer patients and caregivers. The Q&A adds value by addressing common misconceptions. For those familiar with clinical trial design, the content may not be entirely new, but the integration of behavioral examples is a useful contribution.

Pour aller plus loin :

  • Sequential multiple assignment randomized trial — Wikipedia article providing an overview of SMART designs.
  • Adaptive design (medicine) — Concept of adaptive clinical trials, which are distinct from SMARTs; no URL provided due to uncertainty about the exact Wikipedia page.
  • Scoping review — Methodology used by Dr. Lambert to map the literature on SMARTs in behavioral interventions.

145 words

Radar Profile

The radar profile shows high scores in quality, technical level, and reliability, reflecting the expert presenters and rigorous methodology. The quantity of information is slightly lower due to the introductory nature of the talk and the limited number of studies in the scoping review. Overall, the profile indicates a solid, trustworthy presentation suitable for a clinical trials audience.

Reliability 8/10